Beacon Medicare Ltd has begun the promotion of Enzalutamide in the global market under the brand name Enzalunix, a non-steroidal anti-androgen medication that is used in the treatment of prostate cancer.

Enzalunix is a hormonal therapy which is indicated for metastatic castration-sensitive prostate cancer (mCSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).

Beacon, one of the leading oncology drug makers in Bangladesh, will promote Enzalunix in 40mg form and each commercial packet will contain 120 tablets. The company launched the product only for export purposes.

The company authorities believe that the new product will enrich the product chart and will uphold the image and reputation of the company in the global market.